{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:14:04Z","timestamp":1765725244525,"version":"3.48.0"},"reference-count":39,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The aim of this quality improvement project was to improve the turnaround time of B-raf proto-oncogene (BRAF) mutation testing in patients with malignant melanoma to support oncologists in making timely treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective in-house verification of the Idylla BRAF test as compared with DNA panel next-generation sequencing (NGS) performed at an external laboratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Idylla BRAF test had an overall concordance of 95% compared with NGS. This was considered sufficiently good for use in patients with a poor performance status who were at risk of rapid clinical deterioration. Reliable results can be generated using the Idylla BRAF test in tissue sections with tumour neoplastic cell content below 50%. We present a multidisciplinary clinical care algorithm to support dual testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The Idylla BRAF test has the potential to make a significant positive impact on progression-free survival of malignant melanoma patients due to its rapid turnaround time. The Idylla BRAF test can be used as an adjunct to NGS for timely management of patients, particularly those with a poor performance status at presentation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2022-208194","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T13:25:26Z","timestamp":1650029126000},"page":"612-617","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Improving care of melanoma patients through efficient, integrated cellular-molecular pathology workflows using tissue samples with low tumour nuclear content"],"prefix":"10.1136","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2348-6539","authenticated-orcid":false,"given":"Alison","family":"Finall","sequence":"first","affiliation":[{"name":"Cellular Pathology, Swansea Bay University Health Board, Swansea, UK"},{"name":"Medical School, Swansea University, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Murphy","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Pathology Department, Swansea Bay University Health Board, Swansea, UK"},{"name":"Institute of Life Science, Swansea University, Swansea, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricky Dylan","family":"Frazer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Velindre Cancer Centre, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2025121407105632000_76.9.612.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x"},{"key":"2025121407105632000_76.9.612.2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2217\/mmt-2017-0016","article-title":"Anti-Pd-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?","volume":"4","author":"Au","year":"2017","journal-title":"Melanoma Manag"},{"key":"2025121407105632000_76.9.612.3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-017-0458-3","article-title":"The use of immunotherapy in the treatment of melanoma","volume":"10","author":"Achkar","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2025121407105632000_76.9.612.4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14712598.2017.1309388","article-title":"Pembrolizumab use for the treatment of advanced melanoma","volume":"17","author":"Specenier","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2025121407105632000_76.9.612.5","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-196"},{"key":"2025121407105632000_76.9.612.6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.critrevonc.2018.11.002","article-title":"Advanced stage melanoma therapies: detailing the present and exploring the future","volume":"133","author":"Luther","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025121407105632000_76.9.612.7","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-107"},{"key":"2025121407105632000_76.9.612.8","article-title":"Mek inhibition in BRAF-mutated melanoma","volume":"367","author":"Ascierto","year":"2012","journal-title":"N Engl J Med"},{"key":"2025121407105632000_76.9.612.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102253","article-title":"First line treatment of BRAF mutated advanced melanoma: does one size fit all?","volume":"99","author":"Giugliano","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2025121407105632000_76.9.612.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.2452"},{"key":"2025121407105632000_76.9.612.11","doi-asserted-by":"publisher","DOI":"10.1038\/nature09860"},{"key":"2025121407105632000_76.9.612.12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ejca.2017.01.012","article-title":"More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments","volume":"75","author":"Kandolf Sekulovic","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025121407105632000_76.9.612.13","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2021-207987"},{"key":"2025121407105632000_76.9.612.14","unstructured":"Rowlands G . Workforce survey clinical demand report, 2018. Royal College of pathologists. Available: https:\/\/www.rcpath.org\/uploads\/assets\/6dad71d6-8e55-44dd-9a32dd21e7743207\/workforce-survey-clinical-demand-report.pdf"},{"key":"2025121407105632000_76.9.612.15","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4161\/cc.4.10.2026","article-title":"Analysis of BRAF mutation in primary and metastatic melanoma","volume":"4","author":"Libra","year":"2005","journal-title":"Cell Cycle"},{"key":"2025121407105632000_76.9.612.16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/his.13891","article-title":"Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study","volume":"75","author":"Dufraing","year":"2019","journal-title":"Histopathology"},{"key":"2025121407105632000_76.9.612.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2015.09.004"},{"key":"2025121407105632000_76.9.612.18","unstructured":"HTA . Research: standards and guidance. 1st edn, 2016. https:\/\/www.hta.gov.uk\/sites\/default\/files\/Code%20E%20Research%20Standards%20and%20Guidance.pdf: www.hta.gov.uk"},{"key":"2025121407105632000_76.9.612.19","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2008.609"},{"key":"2025121407105632000_76.9.612.20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pathol.3.121806.151541"},{"key":"2025121407105632000_76.9.612.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2012.10.002"},{"key":"2025121407105632000_76.9.612.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70012-9"},{"key":"2025121407105632000_76.9.612.23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz972"},{"key":"2025121407105632000_76.9.612.24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1159\/000449125","article-title":"Two case reports of rare BRAF mutations in exon 11 and exon 15 with discussion of potential treatment options","volume":"9","author":"Richtig","year":"2016","journal-title":"Case Rep Oncol"},{"key":"2025121407105632000_76.9.612.25","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121407105632000_76.9.612.26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40164-017-0067-4","article-title":"Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36\u00a0months","volume":"6","author":"Marconcini","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"2025121407105632000_76.9.612.27","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000099"},{"key":"2025121407105632000_76.9.612.28","unstructured":"CRUK CRU . Melanoma skin cancer incidence statistics. 2018, 2021."},{"key":"2025121407105632000_76.9.612.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10434.x"},{"key":"2025121407105632000_76.9.612.30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jmoldx.2015.12.005","article-title":"Multicenter evaluation of a novel automated rapid detection system of BRAF status in formalin-fixed, paraffin-embedded tissues","volume":"18","author":"Schiefer","year":"2016","journal-title":"J Mol Diagn"},{"key":"2025121407105632000_76.9.612.31","unstructured":"Zhou S , Sivachandran S , Sikorski D . Reflex molecular testing in melanoma diagnosis: when should. J Cutan Med Surg 2021;12034754211045380."},{"key":"2025121407105632000_76.9.612.32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12248"},{"key":"2025121407105632000_76.9.612.33","doi-asserted-by":"crossref","unstructured":"Zhou S , Sikorski D , Xu H . Defining the criteria for reflex testing for. Cancers 2021;13.","DOI":"10.3390\/cancers13092282"},{"key":"2025121407105632000_76.9.612.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.09.007"},{"key":"2025121407105632000_76.9.612.35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CMR.0000000000000421","article-title":"Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, droplet digital PCR, and the Idylla mutation platform","volume":"28","author":"Bisschop","year":"2018","journal-title":"Melanoma Res"},{"key":"2025121407105632000_76.9.612.36","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2019-205970"},{"key":"2025121407105632000_76.9.612.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2019.05.007"},{"key":"2025121407105632000_76.9.612.38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jmoldx.2015.11.006","article-title":"Clinical validation and implementation of a targeted next-generation sequencing assay to detect somatic variants in non-small cell lung, melanoma, and gastrointestinal malignancies","volume":"18","author":"Fisher","year":"2016","journal-title":"J Mol Diagn"},{"key":"2025121407105632000_76.9.612.39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1477750919897380","article-title":"Applying bioethical principles for directing investment in precision medicine","volume":"15","author":"Finall","year":"2020","journal-title":"Clin Ethics"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2022-208194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:11:06Z","timestamp":1765725066000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2022-208194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,17]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/jclinpath-2022-208194"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2022-208194","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}